Antidiabetics Market Dynamics and Analysis by 2031
The Antidiabetics Market is expected to register a CAGR of 12.15% from 2023 to 2031, with a market size expanding from US$ XX million in 2023 to US$ XX Million by 2031.
The research report segments the Antidiabetics Market by Drug Class, Route of Administration, Distribution Channel, and Geography. Global analysis includes regional-level market analysis-major countries in each region are covered under the report. The market share is evaluated for every above-mentioned segment on the basis of US$ million, together with CAGR (%) for the forecast period, which aids in understanding important trends and key dynamics that define the market, along with providing detailed information about market trends and dynamics.
The report has reviewed classes of antidiabetic agents, namely insulin, sulfonylureas, GLP-1 receptor agonists, and DPP-4 inhibitors, describing indications for type 1 and type 2 diabetes. It examines the routes of administration, both oral and injectable, with a view to outlining the innovations and improvements that help improve patient compliance and treatment outcomes.
Regional insights into market demand and accessibility of treatment in key geographies provide a much more granular view, reflecting differences in healthcare infrastructure, prevalence rates, and regulatory environments.
The report Antidiabetics Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:
- Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
- Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
- Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.
Antidiabetics Market Segmentation
Product- Insulin
- Pediatric
- Adult
- Geriatric
- Insulin Pump
- Insulin Syringe/Insulin Pen
- Intravenous Infusion
- Oral
- Others
- Insulin Pump
- Insulin Syringe/Insulin Pen
- Intravenous Infusion
- Oral
- Others
Strategic Insights
Antidiabetics Market Growth Drivers- Rising prevalence of diabetes: Diabetes cases are on the rise worldwide, especially type 2 diabetes, which is generally related to rising obesity rates. According to the International Diabetes Federation, it is estimated that 537 million adults were living with diabetes in 2021, increasing to 643 million by 2030. This alarming trend underlines the urgent need for effective solutions for diabetes management.
- Improvements to the process of drug development: This has taken the form of, but is not limited to, GLP-1 receptor agonists and SGLT2 inhibitors. Newer classes of such drugs provided treatment options with more value and precision for patients. For instance, these newer classes of drugs have achieved major improvements in glycemic control and outcomes related to cardiovascular events, improving adherence among patients to their treatment regimens.
- Aging population: Since older adults is more prone to diabetes, demographic shifts toward an older population in almost all countries are likely to raise demand for antidiabetics. According to the World Health Organization, from 2020 to 2030, it is estimated that the number of people aged 60 years and older will increase from 1 billion to 1.4 billion.
- sedentary lifestyles and poor eating habits: sedentary lifestyles and poor eating habits adding to the burden of diabetes and creating demands for effective treatment modalities. Investments in diabetes research, supported by regulatory bodies, have, in turn, contributed to the overall market outlook through the generation of novel therapies addressing varied patient populations. These factors, when put together, create a very strong environment for growth in the antidiabetics market.
- Advanced Technologies: In the coming years, this might be because of technology advancements, including personalized medicine. Some of the keen trends observed in the market include continuous glucose monitoring systems, the development of new classes of drugs such as SGLT-2 inhibitors, and GLP-1 receptor agonists, along with growing interest in combination therapies.
- Digital Health Solutions: Digital health solutions and telemedicine for diabetes management are on the rise. As the prevalence of diabetes is increasing all over the world, the focus will increasingly be on prevention and early intervention, a process that will shape a more holistic approach to the care of diabetes. Its collaboration with technology companies will further hasten the innovation.
- Nanotechnology in Cancer Treatment: Nanopharmaceuticals are poised to revolutionize cancer treatment through enhanced drug targeting, reduced toxicity, and better imaging techniques. Nanoparticles, like gold nanoparticles and quantum dots, are increasingly being used in cancer therapies for more effective and localized treatment.
- Diabetes Management: The increasing prevalence in the global diabetes market, and a growing focus on newer forms of treatments, opens several investment opportunities within the antidiabetics market. With rising awareness for diabetes management, especially new classes of drugs such as SGLT-2 inhibitors and GLP-1 receptor agonists possessing better efficacy and safety profiles, there is an enormous demand for effective drugs.
- Tailored Treatments: The investment opportunities are increasing due to a growing market for personalized medicine in which more tailored therapies meet the individual needs of patients, thereby improving outcomes and enhancing adherence. This growth is likely to continue to be an exciting area for investment. Further, with digital health solutions, such as telemedicine and mHealth applications, the incidence of growth will increase even further because these technologies allow patients with diabetes to manage and monitor their diseases remotely. Hence, these digital technologies would raise levels of patient interaction and access to care.
- Market Expansion: emerging markets have several growth opportunities due to increasing healthcare spending and growing middle-class demand for better health solutions. Furthermore, the alliances between pharmaceutical companies along technology firms are likely to come up with integrated diabetes management systems. Finally, owing to continuous research and development studies over the discovery of new therapeutic targets and the formula of new drugs, development studies stand dynamic; thus, the antidiabetic market is very fertile ground for implementing long-term investment strategies.
Market Report Scope
Key Selling Points
- Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the Antidiabetics Market, providing a holistic landscape.
- Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
- Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
- Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.
The research report on the Antidiabetics Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.
REGIONAL FRAMEWORK
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The market is expected to register a CAGR of 12.15% during 2023–2031
Key drivers for the antidiabetics market include rising diabetes prevalence, advancements in technology, innovative drug classes, personalized medicine, and increasing adoption of digital health solutions for improved management and prevention.
The antidiabetics market is set for growth through advancements in technology, personalized medicine, and innovative drug classes like SGLT-2 inhibitors and GLP-1 receptor agonists. Digital health solutions and telemedicine will enhance diabetes management and prevention efforts.
Leading companies in this market are - Johnson & Johnson, Bayer Corporation AG, AstraZeneca, Sanofi, Novartis AG, Bristol-Myers Squibb Company, Merck & Co., Inc., Eli Lilly and Company, Pfizer Inc., Novo Nordisk
The report can be delivered in PDF/PPT format; we can also share excel dataset based on the request.
Some of the customization options available based on request are additional 3–5 company profiles and country-specific analysis of 3–5 countries of your choice. Customizations are to be requested/discussed before making final order confirmation, as our team would review the same and check the feasibility.
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Antidiabetics Market - By Product
1.3.2 Antidiabetics Market - By Patient
1.3.3 Antidiabetics Market - By Route of Administration
1.3.4 Antidiabetics Market - By Region
1.3.4.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. ANTIDIABETICS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. ANTIDIABETICS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS, RESTRAINTS & EXPECTED INFLUENCE OF COVID-19 PANDEMIC
6. ANTIDIABETICS MARKET - GLOBAL MARKET ANALYSIS
6.1. ANTIDIABETICS - GLOBAL MARKET OVERVIEW
6.2. ANTIDIABETICS - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. ANTIDIABETICS MARKET - REVENUE AND FORECASTS TO 2028 - PRODUCT
7.1. OVERVIEW
7.2. PRODUCT MARKET FORECASTS AND ANALYSIS
7.3. INSULIN
7.3.1. Overview
7.3.2. Insulin Market Forecast and Analysis
7.3.3. Rapid Acting Analog Market
7.3.3.1. Overview
7.3.3.2. Rapid Acting Analog Market Forecast and Analysis
7.3.4. Long Acting Analog Market
7.3.4.1. Overview
7.3.4.2. Long Acting Analog Market Forecast and Analysis
7.3.5. Premixed Insulin Market
7.3.5.1. Overview
7.3.5.2. Premixed Insulin Market Forecast and Analysis
7.3.6. Short Acting Analog Market
7.3.6.1. Overview
7.3.6.2. Short Acting Analog Market Forecast and Analysis
7.3.7. Intermediate Acting insulin Market
7.3.7.1. Overview
7.3.7.2. Intermediate Acting insulin Market Forecast and Analysis
7.4. DRUG CLASS
7.4.1. Overview
7.4.2. Drug Class Market Forecast and Analysis
7.4.3. Alpha Glucosidase Inhibitors Market
7.4.3.1. Overview
7.4.3.2. Alpha Glucosidase Inhibitors Market Forecast and Analysis
7.4.4. Biguanides Market
7.4.4.1. Overview
7.4.4.2. Biguanides Market Forecast and Analysis
7.4.5. Sulphonylureas Market
7.4.5.1. Overview
7.4.5.2. Sulphonylureas Market Forecast and Analysis
7.4.6. GLP-1 (Glucagon like Peptide) Agonists Market
7.4.6.1. Overview
7.4.6.2. GLP-1 (Glucagon like Peptide) Agonists Market Forecast and Analysis
7.4.7. DPP-IV (Dipeptidyl Peptidase) Inhibitors Market
7.4.7.1. Overview
7.4.7.2. DPP-IV (Dipeptidyl Peptidase) Inhibitors Market Forecast and Analysis
7.4.8. Meglitinides Market
7.4.8.1. Overview
7.4.8.2. Meglitinides Market Forecast and Analysis
7.4.9. SGLT-II (Sodium Glucose Transport Proteins) Inhibitors Market
7.4.9.1. Overview
7.4.9.2. SGLT-II (Sodium Glucose Transport Proteins) Inhibitors Market Forecast and Analysis
7.4.10. Thiazolidinedione Market
7.4.10.1. Overview
7.4.10.2. Thiazolidinedione Market Forecast and Analysis
8. ANTIDIABETICS MARKET - REVENUE AND FORECASTS TO 2028 - PATIENT
8.1. OVERVIEW
8.2. PATIENT POPULATION MARKET FORECASTS AND ANALYSIS
8.3. PEDIATRIC
8.3.1. Overview
8.3.2. Pediatric Market Forecast and Analysis
8.4. ADULT
8.4.1. Overview
8.4.2. Adult Market Forecast and Analysis
8.5. GERIATRIC
8.5.1. Overview
8.5.2. Geriatric Market Forecast and Analysis
9. ANTIDIABETICS MARKET - REVENUE AND FORECASTS TO 2028 - ROUTE OF ADMINISTRATION
9.1. OVERVIEW
9.2. ROUTE OF ADMINISTRATION MARKET FORECASTS AND ANALYSIS
9.3. INSULIN PUMP
9.3.1. Overview
9.3.2. Insulin Pump Market Forecast and Analysis
9.4. INSULIN SYRINGE/ INSULIN PEN
9.4.1. Overview
9.4.2. Insulin Syringe/ Insulin Pen Market Forecast and Analysis
9.5. INTRAVENOUS INFUSION
9.5.1. Overview
9.5.2. Intravenous Infusion Market Forecast and Analysis
9.6. ORAL
9.6.1. Overview
9.6.2. Oral Market Forecast and Analysis
9.7. OTHERS
9.7.1. Overview
9.7.2. Others Market Forecast and Analysis
10. ANTIDIABETICS MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Antidiabetics Market Overview
10.1.2 North America Antidiabetics Market Forecasts and Analysis
10.1.3 North America Antidiabetics Market Forecasts and Analysis - By Product
10.1.4 North America Antidiabetics Market Forecasts and Analysis - By Patient Population
10.1.5 North America Antidiabetics Market Forecasts and Analysis - By Route of Administration
10.1.6 North America Antidiabetics Market Forecasts and Analysis - By Countries
10.1.6.1 United States Antidiabetics Market
10.1.6.1.1 United States Antidiabetics Market by Product
10.1.6.1.2 United States Antidiabetics Market by Patient Population
10.1.6.1.3 United States Antidiabetics Market by Route of Administration
10.1.6.2 Canada Antidiabetics Market
10.1.6.2.1 Canada Antidiabetics Market by Product
10.1.6.2.2 Canada Antidiabetics Market by Patient Population
10.1.6.2.3 Canada Antidiabetics Market by Route of Administration
10.1.6.3 Mexico Antidiabetics Market
10.1.6.3.1 Mexico Antidiabetics Market by Product
10.1.6.3.2 Mexico Antidiabetics Market by Patient Population
10.1.6.3.3 Mexico Antidiabetics Market by Route of Administration
10.2. EUROPE
10.2.1 Europe Antidiabetics Market Overview
10.2.2 Europe Antidiabetics Market Forecasts and Analysis
10.2.3 Europe Antidiabetics Market Forecasts and Analysis - By Product
10.2.4 Europe Antidiabetics Market Forecasts and Analysis - By Patient Population
10.2.5 Europe Antidiabetics Market Forecasts and Analysis - By Route of Administration
10.2.6 Europe Antidiabetics Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Antidiabetics Market
10.2.6.1.1 Germany Antidiabetics Market by Product
10.2.6.1.2 Germany Antidiabetics Market by Patient Population
10.2.6.1.3 Germany Antidiabetics Market by Route of Administration
10.2.6.2 France Antidiabetics Market
10.2.6.2.1 France Antidiabetics Market by Product
10.2.6.2.2 France Antidiabetics Market by Patient Population
10.2.6.2.3 France Antidiabetics Market by Route of Administration
10.2.6.3 Italy Antidiabetics Market
10.2.6.3.1 Italy Antidiabetics Market by Product
10.2.6.3.2 Italy Antidiabetics Market by Patient Population
10.2.6.3.3 Italy Antidiabetics Market by Route of Administration
10.2.6.4 Spain Antidiabetics Market
10.2.6.4.1 Spain Antidiabetics Market by Product
10.2.6.4.2 Spain Antidiabetics Market by Patient Population
10.2.6.4.3 Spain Antidiabetics Market by Route of Administration
10.2.6.5 United Kingdom Antidiabetics Market
10.2.6.5.1 United Kingdom Antidiabetics Market by Product
10.2.6.5.2 United Kingdom Antidiabetics Market by Patient Population
10.2.6.5.3 United Kingdom Antidiabetics Market by Route of Administration
10.2.6.6 Rest of Europe Antidiabetics Market
10.2.6.6.1 Rest of Europe Antidiabetics Market by Product
10.2.6.6.2 Rest of Europe Antidiabetics Market by Patient Population
10.2.6.6.3 Rest of Europe Antidiabetics Market by Route of Administration
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Antidiabetics Market Overview
10.3.2 Asia-Pacific Antidiabetics Market Forecasts and Analysis
10.3.3 Asia-Pacific Antidiabetics Market Forecasts and Analysis - By Product
10.3.4 Asia-Pacific Antidiabetics Market Forecasts and Analysis - By Patient Population
10.3.5 Asia-Pacific Antidiabetics Market Forecasts and Analysis - By Route of Administration
10.3.6 Asia-Pacific Antidiabetics Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Antidiabetics Market
10.3.6.1.1 Australia Antidiabetics Market by Product
10.3.6.1.2 Australia Antidiabetics Market by Patient Population
10.3.6.1.3 Australia Antidiabetics Market by Route of Administration
10.3.6.2 China Antidiabetics Market
10.3.6.2.1 China Antidiabetics Market by Product
10.3.6.2.2 China Antidiabetics Market by Patient Population
10.3.6.2.3 China Antidiabetics Market by Route of Administration
10.3.6.3 India Antidiabetics Market
10.3.6.3.1 India Antidiabetics Market by Product
10.3.6.3.2 India Antidiabetics Market by Patient Population
10.3.6.3.3 India Antidiabetics Market by Route of Administration
10.3.6.4 Rest of Asia-Pacific Antidiabetics Market
10.3.6.4.1 Rest of Asia-Pacific Antidiabetics Market by Product
10.3.6.4.2 Rest of Asia-Pacific Antidiabetics Market by Patient Population
10.3.6.4.3 Rest of Asia-Pacific Antidiabetics Market by Route of Administration
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Antidiabetics Market Overview
10.4.2 Middle East and Africa Antidiabetics Market Forecasts and Analysis
10.4.3 Middle East and Africa Antidiabetics Market Forecasts and Analysis - By Product
10.4.4 Middle East and Africa Antidiabetics Market Forecasts and Analysis - By Patient Population
10.4.5 Middle East and Africa Antidiabetics Market Forecasts and Analysis - By Route of Administration
10.4.6 Middle East and Africa Antidiabetics Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Antidiabetics Market
10.4.6.1.1 South Africa Antidiabetics Market by Product
10.4.6.1.2 South Africa Antidiabetics Market by Patient Population
10.4.6.1.3 South Africa Antidiabetics Market by Route of Administration
10.4.6.2 Saudi Arabia Antidiabetics Market
10.4.6.2.1 Saudi Arabia Antidiabetics Market by Product
10.4.6.2.2 Saudi Arabia Antidiabetics Market by Patient Population
10.4.6.2.3 Saudi Arabia Antidiabetics Market by Route of Administration
10.4.6.3 U.A.E Antidiabetics Market
10.4.6.3.1 U.A.E Antidiabetics Market by Product
10.4.6.3.2 U.A.E Antidiabetics Market by Patient Population
10.4.6.3.3 U.A.E Antidiabetics Market by Route of Administration
10.4.6.4 Rest of Middle East and Africa Antidiabetics Market
10.4.6.4.1 Rest of Middle East and Africa Antidiabetics Market by Product
10.4.6.4.2 Rest of Middle East and Africa Antidiabetics Market by Patient Population
10.4.6.4.3 Rest of Middle East and Africa Antidiabetics Market by Route of Administration
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Antidiabetics Market Overview
10.5.2 South and Central America Antidiabetics Market Forecasts and Analysis
10.5.3 South and Central America Antidiabetics Market Forecasts and Analysis - By Product
10.5.4 South and Central America Antidiabetics Market Forecasts and Analysis - By Patient Population
10.5.5 South and Central America Antidiabetics Market Forecasts and Analysis - By Route of Administration
10.5.6 South and Central America Antidiabetics Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Antidiabetics Market
10.5.6.1.1 Brazil Antidiabetics Market by Product
10.5.6.1.2 Brazil Antidiabetics Market by Patient Population
10.5.6.1.3 Brazil Antidiabetics Market by Route of Administration
10.5.6.2 Argentina Antidiabetics Market
10.5.6.2.1 Argentina Antidiabetics Market by Product
10.5.6.2.2 Argentina Antidiabetics Market by Patient Population
10.5.6.2.3 Argentina Antidiabetics Market by Route of Administration
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. ANTIDIABETICS MARKET, KEY COMPANY PROFILES
12.1. ELI LILLY COMPANY
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. BAYER CORPORATION AG
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. NOVARTIS AG
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. JOHNSON AND JOHNSON
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. ASTRAZENECA
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. PFIZER INC
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. BRISTOL-MYERS SQUIBB
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. NOVO NORDISK
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. MERCK AND CO
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. SANOFI
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
1. Johnson & Johnson
2. Bayer Corporation AG
3. AstraZeneca
4. Sanofi
5. Novartis AG
6. Bristol-Myers Squibb Company
7. Merck & Co., Inc.
8. Eli Lilly and Company
9. Pfizer Inc.
10. Novo Nordisk
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For